Clinic Software← All companies
Orbit Genomics
The Future of Precision Medicine – transforming complex disease diagnosis, treatment and prevention.
health AImedtechdigital health
Stageseed
Raised$780K to $4.08M
Employees5
LocationBoulder, CO
Business modelB2B, B2B2C, SaaS
About
Orbit Genomics is a precision healthcare company that is transforming diagnosis, treatment and prevention of complex diseases including cancer, heart disease and neurological diseases. The company’s patented, AI-enabled OrbiSeq™ platform analyzes that analyzes a previously inaccessible and highly informative class of genetic variation relevant to disease diagnosis, risk stratification, and intervention across complex diseases and aging. The company's first product is a blood test to diagnose early stage lung cancer.
Product
- Value proposition
- OrbiSeq platform enables genome-wide analysis of repetitive DNA to enable accurate, non-invasive diagnosis and precision intervention across complex diseases, including early diagnosis of cancer from blood tests.
- Target customers
- Healthcare providers, hospitals, cancer centers, diagnostic labs
Founders
- Harold Garner — Co-Founder, Chief Scientific Officer, and Director
- Dede Willis — Co-Founder, CEO, President, and Director
- Randy Berholtz — Founder, General Counsel, and Vice President Business Development
- Mikael Ørum — Founder and Chair
Categories
Products
OrbiSeq-LOrbiSeq™ platform
Key features
AI-enabled analysis of repetitive DNA (STRs)Non-invasive diagnostic tests from bloodGenome-wide STR analysisClinically actionable genomic products
Technologies
OrbiSeq™short tandem repeats (STRs) analysisAI/machine learning
Integrations
EHRs / clinical data systems (unspecified)
Target conditions
Lung cancerIndeterminate pulmonary nodules (IPNs)Complex diseasesCardiovascular diseasesNeurological diseasesHealthy aging and longevity
Care settings
HospitalClinicLaboratoryHome (at-home sampling potential)
Awards
Startup Prize Focus on Health 2025 (Non-FDA track) grand prize winner
Traction metrics
Lead product OrbiSeq-L for IPN lung cancer diagnosisNon-invasive blood test capability
Competitors
Other genomics diagnostic companies focusing on non-invasive cancer diagnostics (not explicitly listed)
Investors
National Institutes of HealthCancerX (USA)New Horizon HealthNew Mexico AngelsNHH VenturesPlug and Play APACRockies Venture ClubColorado Office of Economic Development and International Trade
News
- How Orbit Genomics Is Revolutionizing Early Cancer Detection with a Non-Invasive Blood Test - MassChallenge · 2025-09-25T14:12:17.000Z
- Orbit Genomics Wins Startup Prize Focus on Health (Non-FDA Track) – Orbit Genomics · 2025-08-25T00:00:00.000Z
- Orbit Genomics, Inc. was awarded a two-year, $2million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer blood test – Orbit Genomics · 2024-09-23T00:00:00.000Z
- Orbit Genomics Named Finalist in Startup Prize Focus on Health – Orbit Genomics · 2025-07-28T00:00:00.000Z
- AI-based Medical Device Company Imidex and Orbit Genomics Form Strategic Relationship to Explore the Detection of Lung Cancer in Early Stages – Orbit Genomics · 2024-08-27T00:00:00.000Z
- Orbit Genomics Appoints Strategic Communications and Capital Markets Leader Julie Silber to Board of Directors – Orbit Genomics · 2025-06-18T00:00:00.000Z
